Skip to main content

Table 2 Results of the Base-case and Scenario Analyses

From: Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma

  

COST ($)

QALY

LYs

ICER($/QALY)

Base case

     

 Sintilimab + Bevacizumab

33,102

1.431

2.04

24,462

 Lenvatinib

21,037

0.938

1.32

-

Scenario

     

 Sintilimab + Bevacizumab

24,752

1.431

2.04

7,533

 Lenvatinib

21,037

0.938

1.32

-

  1. QALY: quality-adjusted life-year; LYs: life-years; ICER: incremental cost-effectiveness ratio
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us